MIMEDX GROUP, INC. (NASDAQ:MDXG) Files An 8-K Financial Statements and ExhibitsItem 9.01Financial Statements and Exhibits.
(d)Exhibits
|
10.1 |
Third Amendment dated as of March 30, 2018, to Credit Agreement dated as of October 12, 2015, by and among MiMedx Group, Inc., a Florida corporation, the Guarantors identified on the pages hereto, the Lenders identified on the pages hereto and Bank of American, N.A., in its capacity as administrative agent.
|
MIMEDX GROUP, INC. ExhibitEX-10.1 2 ex1018-k422018locamendment.htm THIRD AMENDMENT TO CREDIT AGREEMENT Exhibit Exhibit 10.1THIRD AMENDMENT THIS THIRD AMENDMENT (this “Amendment”) dated as of March 30,…To view the full exhibit click here
About MIMEDX GROUP, INC. (NASDAQ:MDXG)
MiMedx Group, Inc. (MiMedx) is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues and human skin and bone. The Company operates in the Regenerative Biomaterials business segment, which includes the development, processing and marketing of regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues in the wound care, surgical, sports medicine, ophthalmic and dental market categories. Its biomaterial platform technologies are AmnioFix, EpiFix, OrthoFlo, Physio, AlloBurn, and CollaFix. AmnioFix and EpiFix are its tissue technologies processed from human amniotic membrane derived from donated placentas. The Company processes the human amniotic membrane utilizing its PURION Process, to produce an implant. MiMedx is the supplier of amniotic tissue, having supplied over 500,000 allografts.